Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Localization update: place names now use the Tatar-language form ‘Respublika’ (e.g., Kazan’, Tatarstan, Respublika, Russia, 420029) instead of ‘Tatarstan Republic’; page revision bumped to v3.0.2, with a minor removal of the Back to Top element.
    Difference
    0.2%
    Check dated 2025-09-15T19:30:31.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-08T15:05:13.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, particularly in Europe, Asia, and Latin America. Additionally, new content related to drug safety and specific drugs has been introduced.
    Difference
    16%
    Check dated 2025-09-01T09:30:57.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.0%
    Check dated 2025-08-18T02:16:32.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.0%
    Check dated 2025-08-11T00:11:35.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.4%
    Check dated 2025-08-03T17:58:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.